Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies
M Jongbloed, AA Khosla, V Bartolomeo… - Current oncology …, 2024 - Springer
Abstract Purpose of Review This review discusses the definitions, treatment modalities,
management, future directions, and ongoing clinical trials of oligoprogressive disease in …
management, future directions, and ongoing clinical trials of oligoprogressive disease in …
[HTML][HTML] First-versus third-generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with brain metastases
Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis
Importance Epidermal growth factor receptor inhibitors (EGFRis) have been reported to be
associated with cutaneous and ocular side effects; however, there is limited evidence of an …
associated with cutaneous and ocular side effects; however, there is limited evidence of an …
[HTML][HTML] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung …
Objectives The irreversible epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation …
(EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation …
[HTML][HTML] Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced …
D Zhang, X Liu, F Shen, D Zhao, Y Shi… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background In the phase 3 FLAURA trial, osimertinib was compared with first-generation
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line …
Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study
O Manninen, L Puuniemi, S Iivanainen, M Arffman… - Acta …, 2023 - Taylor & Francis
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are a
standard of care treatment options in non-small cell lung cancer (NSCLC). The present study …
standard of care treatment options in non-small cell lung cancer (NSCLC). The present study …
[HTML][HTML] Improvement in survival for patients with lung cancer in Taiwan: implications and call to action
F Oezkan, M Seweryn, T Shukuya, DH Owen - Journal of Thoracic …, 2023 - Elsevier
Lung cancer screening by low-dose computed tomography (LDCT) scan has been initiated
in several countries around the globe after large-scale studies revealed a significant …
in several countries around the globe after large-scale studies revealed a significant …
Optimal First-Line Treatment for EGFR-Mutated NSCLC: A Comparative Analysis of Osimertinib and Second-Generation EGFR-TKIs
Background Osimertinib is an irreversible third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). It is the preferred first-line treatment for EGFR-mutated …
(EGFR) tyrosine kinase inhibitor (TKI). It is the preferred first-line treatment for EGFR-mutated …